August M&A Activity and Details

Biotech Markets Pricing in Rate Cuts as Index Stays Above 50-Day Average.

Record Low Volumes but Biotech Catching a Tailwind with Expectations of Rate Cuts

Low Trading Volume Reflects Wait and See Approach to Rates, Market Volatility

Biotech Capital Markets Highlights: Transactions 2X Over 2023

Government Announces Drug Price Controls

Earnings Season Continues with Beats. Market Poised for a Breakout but Appears Waiting on Rates

Biotech Stays Above 50-Day Moving Average and Crown Therapeutics Acquires Revance for $924M

Diving Into the Mortgage and Housing Market - Prices Remain High, Inventory Low, But the Future of Rates Has Investors, Borrowers, and Owners Engaged

A Look at Biotech Earnings Beats and Misses - Overall a Solid Quarter

The 10-year Yield Falls with S&P Biotech Index - Trends Breaking and Sector Optimistic

Collegium Acquires Ironshore Therapeutics for $525M and Big Pharma Rallies on Strong Earnings and IRA Policy Impact

There Is Still No Market Volatility! One 2% Up Day and Zero -2% Down Days in Almost a Year

Breaking Down of Momentum as a Leading Performance Metric Continues to Influence Biotech Sector

Why Are Fixed Income Managers Staring at SOFR Rates and Why Does Their Coming Down Matter?

Illumnia Acquires Fluent Biosciences and CMS Rule Changes Ignite Lantheus Holdings Up +35% As Biotech Continues Its Summer Bump

July 2024 Riffin' on Real Estate

Eli Lilly Continues Its Run Acquiring Morphic Holdings for $3.2B As Its Stock Pushes +62% for the Year

Biotech Index Moves to Market Cap Weighted Style and Healthcare Report Forecasts Spending to 19.7% of GDP by 2032!